Market Intelligence for Long-Acting Formulations, Antagonist Development, and High-Purity Reagents for Growth Disorders.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for GH1/HGH drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GH1 (HGH) Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native folding. |
View GH1 Products |
| Gene Delivery | GH1 ORF Lentivirus Full-length ORF for stable cell line construction and secretion assays. |
View GH1 Products |
| Benchmark Ab | Anti-GH1 Neutralizing Antibody Recombinant control for antagonist potency assays. |
View GH1 Products |
| Validator | GH1 siRNA Set For knockdown verification in pituitary adenoma cell models. |
View GH1 Products |
| Related Target: GHR | Growth Hormone Receptor Binding partner for GH1; essential for receptor binding and dimerization assays. |
View GHR Products |
| Related Target: IGF1 | Insulin-like Growth Factor 1 Downstream effector; synergy analysis in growth proliferation assays. |
View IGF1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Long-acting variant screening (half-life extension) | High-purity WT and mutant GH1 proteins with defined secondary structure; Endotoxin-controlled (<1 EU/µg) for sensitive cell-based assays |
| Cross-species cyno/mouse/rat evaluation | Human/Mouse/Cyno ortholog proteins available with >95% purity; Sequence-verified for conserved epitope mapping |
| Antagonist potency quantification (vs. Pegvisomant benchmarks) | GHR ECD-Fc fusion protein (HEK293 expressed) for SPR/BLI binding inhibition assays with native glycosylation |
| Bioactivity standardization | Theoretical MW confirmation via mass spec; High-purity reference standard for proliferation assays (Ba/F3-GHR) |
Live GH1/HGH R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GH1 therapeutics is intensifying, with major players shifting focus from daily injections to long-acting weekly formulations. As first-generation long-acting therapies (Somapacitan, Somatrogon, TransCon hGH) reach the market, the next wave of R&D is targeting tissue-specific delivery and antagonist development for acromegaly and cancer cachexia.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Long-Acting Agonist | Novo Nordisk, Pfizer, Ascendis | Growth Hormone Deficiency (Pediatric/Adult) | Binding Kinetics Assay (Need high-purity GH1 variants with confirmed conformation) |
| GHR Antagonist | Novo Nordisk, Chiasma | Acromegaly | Competitive Binding Assay (Need GH1 + GHR ECD-Fc pairs) |
| Biosimilar | Sandoz, Merck, Genentech | GHD, Turner Syndrome, SGA | Immunogenicity Testing (Need sequence-verified reference standards) |